Trokendi XR 50 mg Capsules Recall Over Failed Dissolution Specifications

Source: FDA · United States

Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.

Supernus Pharmaceuticals, Inc. is recalling 11,304 bottles of Trokendi XR (topiramate) extended-release capsules due to failed dissolution specifications.

FDA recall: what the record actually shows

This notice was issued by FDA on September 14, 2026 and geographically references United States. The FDA classifies this as a Class III recall, with the stated reason "Failed dissolution specifications.", distributed us nationwide.. FDA recall classes run from I (reasonable probability of serious harm) to III (unlikely to cause harm), so the class number is the fastest way to gauge severity here. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

It is tempting to skim, check personal relevance, and move on. The better habit is confirming scope, source, and timestamp first, then reading this alongside related notices instead of drawing a conclusion from one record alone.

The original agency source is linked below so you can verify this record directly before acting on it. Its related labels are recall, product-safety, fda, drugs.

What Happened

Supernus Pharmaceuticals, Inc. initiated a voluntary recall of Trokendi XR due to failed dissolution specifications.

Which Products Are Affected

Trokendi XR (topiramate) extended-release capsules, 50 mg, 30 Capsules, Rx only, NDC 17772-102-30. Lot# 2145283, Exp Date: 31-Mar-2030. 11,304 bottles distributed nationwide in the United States.

What You Should Do

No specific consumer actions are detailed in the recall notice.

Why This Matters

This is a Class III recall involving a prescription drug that failed quality specifications.

Source

FDA recall number D-0833-2026, report date 2026-09-09.

Original source: FDA Official Notice ↗

All FDA Recalls →

Nationwide notices with similar length or severity timing 8

Two Areazine-derived peer sets for this FDA recall: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.

Questions & Answers

What people usually ask about a notice like this one.

What is this FDA recall about?
Supernus Pharmaceuticals, Inc. is recalling 11,304 bottles of Trokendi XR (topiramate) extended-release capsules due to failed dissolution specifications.
Which agency issued this alert?
This alert was issued by FDA. The original notice is available at the source link at the bottom of this article.
How is this recall classified, and why does that matter?
The FDA classifies this as a Class III recall, citing "Failed dissolution specifications." as the reason. Class I is the most serious (reasonable probability of serious harm), Class II is a moderate or temporary health risk, and Class III is unlikely to cause harm.
What area is affected?
This alert affects United States. Check with FDA for the most current geographic scope.
Where can I find more FDA Recalls updates?
Browse the full FDA Recalls feed on Areazine at areazine.com/recalls/fda/ for the latest updates from FDA and other agencies.